Sign In

Charlotte Guzzo

Founder and COO @Sano Genetics

Charlotte Guzzo is the co-founder and COO of Sano Genetics, a company with a mission to advance personalized medicine globally.

She has a diverse educational background, including studies in Genetics, Entrepreneurship, Neuroscience, Law, and Classics from prestigious institutions like the University of Cambridge and the University of Paris I: Panthéon-Sorbonne.

Charlotte Guzzo's professional experience includes roles at Wellcome Sanger Institute, JPMorgan Chase & Co., and Rajah & Tann Asia, where she gained expertise in postgraduate research, risk management, regulatory practices, and corporate initiatives.

As the former Co-Founder & COO at Sano Genetics, Charlotte has played a key role in developing a 360* platform that integrates genetic testing, recruitment, and engagement to facilitate precision medicine initiatives for patient benefit.

Highlights

Aug 19 · linkedin

🔬 Imagine a world where genetic testing is not just fast and accurate but also affordable and scalable. We're already there.

Technological advances have radically reduced the time and cost involved in generating genomic data, improving our ability to store, access, and analyse it. This progress is driving genetic research forward, making personalised medicine a reality by enabling researchers to collaborate on a global scale. And as the volume of genomic data produced —currently estimated at around 220 million genomes annually—continues to grow, technology will continue to be key in making effective use of this data and ultimately benefitting patients.

When I think about these advancements, here's what's most exciting from my perspective:

Cost efficiency: Short-read technology offers the lowest cost per base for gene sequencing, making it economical for large-scale studies. Speed: High-throughput sequencing generates millions to billions of reads quickly, crucial for timely clinical decisions. Accuracy: Short-read technology boasts an accuracy rate of >99.9% in base-calling. Scalability: Easily automated and scaled, allowing large numbers of samples to be processed simultaneously.

I’ve never been more excited about the potential these advancements bring. It’s a pivotal time for precision medicine and patient care.

❓How is genetic testing benefiting your research? Shoot me a DM and let me know; I'm eager to discuss!

♻️ And feel free to share this post to keep this important conversation going.

Jul 15 · linkedin

I am incredibly proud of our collaboration with @Prevail (now part of @Lilly)! 🌟

With 40% of Frontotemporal Dementia (FTD) cases having a genetic link, Prevail’s program is instrumental in identifying individuals with these mutations and connecting them to clinical trial opportunities.

Over the past ten months, we have successfully recruited, tested, and provided genetic counselling to participants across the US. We’ve also surpassed our initial targets, expanded our reach to Spanish-speaking communities, and are now preparing to scale our efforts across Europe, Australia, and North America. 🌎

To learn more, shoot me a note!#globalclinicaltrials

Charlotte Guzzo
Add to my network

Location

Greater Cambridge Area